Scientific Sessions 2025  /  Groundbreaking Trials in Cardiometabolic Therapeutics  /  Discussant: VESALIUS-CV trial
Logo

American Heart Association

  61
  0

Final ID:

Discussant: VESALIUS-CV trial

  • Morris, Pamela  ( MEDICAL UNIVERSITY OF SC , Mt Pleasant , South Carolina , United States )
    • Author Disclosures:
    Pamela Morris: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Groundbreaking Trials in Cardiometabolic Therapeutics

Saturday, 11/08/2025 , 08:30AM - 09:45AM

Late-Breaking Science

More abstracts on this topic:
Discussant

Lingvay Ildiko, Rosenson Robert

DR10624, a First-In-Class, FGF21 Receptor/Glucagon Receptor/GLP-1 Receptor Triple Agonist, Rapidly and Significantly Reduced Triglycerides, Atherogenic Lipids, and Liver Fat in Patients With Severe Hypertriglyceridemia: Primary Results From a Randomized Phase 2 Trial.

Li Jianping, Zhou Zijian, Lv Lingchun, Gan Yulong, Wang Ying, Zhu Chaonan, Xu June, Huang Yanshan, Fang Yongliang, Zhang Long, Fan Yanting, Zhang Shu, Wang Liyun, Qu Yanling, Yin Guotian, Jiang Hongwei

More abstracts from these authors:
Treatment Implications of LDL-Cholesterol and Apolipoprotein B Discordance: Insights from the Very Large Database of Lipids (VLDbL) and the National Health and Examination Survey (NHANES)

Peng Allison, Blumenthal Roger, Martin Seth, Zahid Sohail, Gianos Eugenia, Shapiro Michael, Navar Ann Marie, Marvel Francoise, Rodriguez Fatima, Soffer Daniel, Morris Pamela

History and future of lipid therapeutics- a time of Renaissance

Rader Daniel, Morris Pamela

You have to be authorized to contact abstract author. Please, Login
Not Available